November 30, 2006

CHDP Provider Information Notice No.: 06-13

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP) PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

SUBJECT: ADDITION OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE AS A CHDP BENEFIT, REPORTING CODES, REIMBURSEMENT FOR VACCINE ADMINISTRATION, AND UPDATED CHDP VACCINE BENEFIT AND REIMBURSEMENT TABLE

The purpose of this Provider Information Notice is to inform you that the HPV vaccine has been added as a CHDP program benefit.

This Information Notice provides the new CHDP administration code and billing and reimbursement information. An updated CHDP vaccine benefit and reimbursement table is enclosed that includes the addition of this new vaccine. A Vaccine for Children (VFC) Provider Letter is enclosed that contains additional information on the vaccine.

On June 8, 2006, the Food and Drug Administration approved HPV vaccine (Gardasil™), the first vaccine for cervical cancer prevention, for females’ ages 9 to 26 years. Gardasil™, a quadrivalent vaccine, protects against four HPV types (6, 11, 16, 18), which are responsible for 70 percent of cervical cancers and 90 percent of genital warts. Annually, nearly 4000 women in the U.S. die from cervical cancer.

The Advisory Committee on Immunization Practices and the VFC Program issued a resolution on June 29, 2006, to add HPV vaccine to the VFC Program. The vaccine is given in 3 intramuscular injections over 6 months, with the second and third doses given 2 and 6 months after the first dose. The VFC Program will provide vaccine for females 9 through 18 years, with an emphasis on 11 to 12 year olds. A Vaccine Information Statement is available at http://www.cdc.gov/nip/publications/VIS/vis-hpv.pdf.

HPV vaccine can be given to females who have an equivocal Pap test, a positive Hybrid Capture II™ high risk test, or genital warts. Though data from clinical trials do not
indicate that the vaccine will have any therapeutic effect on existing Pap test abnormalities, HPV infection or genital warts, vaccination of these females would provide protection against infection with vaccine HPV types not already acquired.

HPV vaccine is contraindicated for females with a history of immediate hypersensitivity to yeast or to any vaccine component. The vaccine can be administered to females with minor acute illnesses, but should be deferred until after the illness improves for those with moderate or severe acute illnesses. HPV vaccine is not recommended for use in pregnancy.

**HPV Vaccine as a CHDP Program Benefit**

Effective November 1, 2006, CHDP will reimburse providers for the administration fee of HPV vaccine to CHDP eligible female children; the vaccine will be provided at no charge by the VFC Program for these children. The CHDP vaccine code is 76 and has the reimbursement rate of $9.00 for the administration fee. This vaccine is not available for purchase at this time.

<table>
<thead>
<tr>
<th>Human Papillomavirus (HPV) Vaccine</th>
<th>76</th>
<th>VFC</th>
<th>9 years thru 18 years 11 months</th>
<th>$9.00</th>
</tr>
</thead>
</table>

Code 76 is payable for three doses. HPV vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tetanus, Diphtheria, and Acellular Pertussis (Tdap) and Meningococcal Conjugate (MCV4) vaccines. HPV vaccine has been added to the Vaccine Codes and Rates Table found in the rates max CHDP section of the CHDP Provider Manual.

**Reminder:**

All CHDP program providers actively involved with immunized children must participate in the VFC Program, which provides vaccines at no cost to the provider for eligible children up to eighteen years eleven months. The CHDP Program reimburses only the immunization administration fee for VFC covered vaccines.
Billing Instructions for HPV Vaccine

Please use the following instructions for billing for HPV Vaccine. Refer to the CHDP Provider Manual for additional information.

- Enter the CHDP Code number, 76, and HPV on a blank line, under the immunization section of the PM 160 Confidential Screening/Billing Report.

- Enter a check mark in only one of the Immunization Outcome Columns (A or B) of the PM 160, as appropriate.

- Enter the administration fee in the Fees Column (Note: fees do not apply on the "Information Only" PM 160).

- If you have administered HPV vaccine on or after November 1, 2006, and prior to this notice, you are entitled to reimbursement for the administration of this vaccine. Please submit a PM 160 for the $9.00 administration fee if you have not been previously reimbursed for the vaccine by any source.

CHDP Vaccine Benefits and Reimbursement Table

An updated CHDP Vaccine Benefit and Reimbursement Table are enclosed; it is dated November 1, 2006. The table includes the HPV vaccine code and reimbursement rate.

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions about CHDP vaccine benefits or other CHDP issues, please contact your local CHDP program office.

Original Signed by Marian Dalsey, M.D., M.P.H.

Marian Dalsey, M.D., M.P.H., Chief
Children’s Medical Services Branch

Enclosures
December 4, 2006

TO:   California Vaccines for Children (VFC) Program Providers

FROM:   Howard Backer, M.D., M.P.H., Chief
          Immunization Branch

SUBJECT:  QUADRIVALENT HUMAN PAPILLOMAVIRUS (HPV) RECOMBINANT
          VACCINE IS NOW AVAILABLE FROM VFC

This memo is divided into sections to enable you to quickly access the information you need:

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary</td>
<td>1</td>
</tr>
<tr>
<td>Background and Composition</td>
<td>2</td>
</tr>
<tr>
<td>Recommendations for Vaccine Use</td>
<td>2</td>
</tr>
<tr>
<td>How Supplied for California VFC Program Providers</td>
<td>3</td>
</tr>
<tr>
<td>Ordering and Billing</td>
<td>3</td>
</tr>
<tr>
<td>Potential Vaccine Reactions</td>
<td>4</td>
</tr>
<tr>
<td>Contraindications</td>
<td>4</td>
</tr>
<tr>
<td>Precautions</td>
<td>4</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>4</td>
</tr>
<tr>
<td>Special Situations</td>
<td>4</td>
</tr>
<tr>
<td>Documentation</td>
<td>5</td>
</tr>
</tbody>
</table>

SUMMARY

On June 8, 2006, United States Food and Drug Administration (FDA) licensed a quadrivalent human papillomavirus vaccine (trade name Gardasil™, Merck & Co., Inc.), for use in females ages 9-26 years. The Advisory Committee on Immunization Practices (ACIP) voted at their June 2006 meeting to recommend the routine use of quadrivalent HPV vaccine as a three-dose series for females ages 11-12 years. Quadrivalent HPV vaccine is also recommended for females ages 13-26 years who did not complete or receive the vaccine when they were younger. The series can be started in females as young as the age of nine years. Quadrivalent HPV vaccine is now available from the VFC Program (http://www.cdc.gov/nip/vfc/acip_vfc_resolutions.htm) for females 9 through 18 years of age. This letter summarizes information about the use of quadrivalent HPV vaccine in the VFC program. The Immunization Branch is following ACIP’s provisional recommendations for use of this quadrivalent HPV vaccine. Once available, the Immunization Branch will provide ACIP’s final recommendations as well as any updated vaccine information.
BACKGROUND AND COMPOSITION

Human papillomavirus types 16 and 18 cause approximately 70 percent of cervical cancer cases along with some cases of other less common anogenital cancers and cancers of the head and neck. Human papillomavirus types 6 and 11 cause approximately 90 percent of genital warts. Quadravalent HPV vaccine is a prophylactic vaccine against human papillomavirus types 6, 11, 16, and 18; it is not intended as a treatment for active disease or current infection. The vaccine has not been shown to protect against disease caused by non-vaccine HPV types.

Gardasil™ is a non-infectious recombinant, quadrivalent vaccine prepared from highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus types 6, 11, 16, and 18. The L1 proteins are produced by fermentation in recombinant yeast cells. Quadrivalent HPV vaccine is a sterile liquid suspension that contains the adsorbed VLPs of each HPV type, aluminum-containing adjuvant, and purification buffer. After thorough agitation, quadrivalent HPV vaccine is a white, cloudy liquid. The product does not contain any preservative or antibiotics.

In women who were not infected with the human papillomavirus types 16 and 18 prior to dose one and through one month after dose three, quadrivalent HPV vaccine had an efficacy of 100 percent against high grade cervical, vulvar or vaginal cancer precursors [CIN2/3, AIS, VIN2/3, ValN2/3] associated with human papillomavirus types 16 and 18. Quadrivalent HPV vaccine had an efficacy of 95 percent against any grade of cervical intraepithelial neoplasia (CIN) [CIN1, CIN2/3] or adenocarcinoma in situ (AIS) related to human papillomavirus types 6, 11, 16, and 18. The vaccine had an efficacy of 99 percent against genital warts associated with human papillomavirus types 6, 11, 16, and 18. The vaccine does not protect against HPV types already acquired prior to vaccination.

RECOMMENDATIONS FOR VACCINE USE

Eligible Persons for Receipt of VFC Vaccine

Females ages 9 through 18 years are eligible for quadrivalent HPV vaccine provided by the VFC program.

Dosing Schedule

Routine immunization with three doses of quadrivalent HPV vaccine is recommended for females 11-12 years of age. The vaccination series can be started in females as young as nine years of age. Catch-up vaccination is recommended for females 13-26 years of age who have not been vaccinated previously or who have not completed the full vaccine series, though VFC vaccine is not available past the age of 18 years. Ideally, the vaccine should be administered before potential exposure to HPV through sexual contact; however, females who are already sexually active should still be vaccinated.

At present, cervical cancer screening recommendations have not changed for females who receive the HPV vaccine. Thirty percent of cervical cancers are caused by HPV types that are not prevented by the HPV vaccine, and sexually active females could have been infected prior to vaccination. Providers should continue to educate women about the importance of cervical cancer screening.

Quadrivalent HPV vaccine should be administered intramuscularly as a series of three separate 0.5 mL doses. The second dose should be given two months after the first dose, and the third dose should be given six months after the first dose.
**Administration**
Thoroughly shake the vial prior to use. The vaccine should appear as a white, cloudy liquid after agitation. The vaccine should be inspected visually for particulate matter and discoloration prior to administration. Do not use the product if particulates are present or if it appears discolored. For single dose vials, 0.5 mL dose of the vaccine should be withdrawn from the single-dose vial using a sterile needle and syringe free of preservatives, antiseptics, and detergents. Once the single-dose vial has been penetrated, the withdrawn vaccine should be used promptly, and the vial must be discarded.

**Administration with other vaccines**
Quadrivalent HPV vaccine may be given at the same visit when other age appropriate vaccines are provided, such as Tdap and MCV4.

**HOW SUPPLIED FOR CALIFORNIA VFC PROGRAM PROVIDERS**

**Vials**
Gardasil™ is supplied as a carton of ten 0.5mL single dose vials (NDC 0006-4045-41).

**Storage**
- Quadrivalent HPV vaccine should be refrigerated at 36 - 46 degrees F (2 - 8 degrees C).
- Do not freeze.
- Protect from light.

**ORDERING AND BILLING**

**How to Order**
VFC Providers may order quadrivalent HPV vaccine using the enclosed VFC Vaccine Order Form (DHS 8501 (11/06)). Vaccine orders for this vaccine should be based on the number of VFC-eligible females, in the recommended age category, expected to be seen at your practice during the particular ordering period. Previous usage of vaccines routinely recommended for adolescents in the 11-12 years age range, such as Tdap, may be useful in guiding your initial vaccine order.

Although VFC providers are encouraged to submit vaccine orders every two months, a separate vaccine request for HPV vaccine may be submitted if a regular order for pediatric vaccines has been recently submitted to the VFC Program Office. Otherwise, providers should order HPV vaccine at the same time other pediatric vaccines are ordered. Information is required in all the four columns of the order form to process vaccine orders. Remember to maintain a copy of your order forms for your office files.

Please be aware that your orders of quadrivalent HPV vaccine may be adjusted, especially during this introductory phase.

**Billing Information for VFC Vaccine**
Children's Health and Disability Prevention (CHDP): Claims may be submitted for doses of quadrivalent HPV vaccine administered on or after November 1, 2006. The CHDP administration fee is $9.00 using CHDP code 76. However, providers should wait until notified by CHDP to submit claims. CHDP Provider Information Notices can be found at [http://www.dhs.ca.gov/pcfh/cms/onlinearchive/chdppl.htm](http://www.dhs.ca.gov/pcfh/cms/onlinearchive/chdppl.htm).
Medi-Cal Fee-For-Service (FFS): The CPT code for administration of quadrivalent HPV vaccine for Medi-Cal is 90649-SL.

Other codes for the use of quadrivalent HPV vaccine that is not supplied by VFC:

- The CPT code for quadrivalent HPV vaccine is 90649.
- The CPT code for administration of quadrivalent HPV vaccine is 90471 if given alone, and +90472 if given after (an) additional vaccine(s) at the same visit (e.g., if Tdap and HPV vaccine are given at the same encounter then one of the vaccine administration codes will be 90471 and the other +90472).
- The ICD-9-CM code for quadrivalent HPV vaccine is V05.8.

POTENTIAL VACCINE REACTIONS

Serious Adverse Events: The most frequently reported serious adverse events in trials were headache (0.03% vs. 0.02% placebo), gastroenteritis (0.03% vs. 0.01%), appendicitis (0.02% vs. 0.01%), and pelvic inflammatory disease (0.02% vs. 0.01%). Other serious adverse events were rare. Subjects were also evaluated for new medical conditions over the four year follow-up, including systemic immune disorders (0.076% vs. 0.031% placebo). Post licensure safety studies will be conducted to more closely assess safety of the vaccine.

Minor Adverse Events: Quadrivalent HPV vaccine has been associated with pain (84%), swelling (25%), redness (25%) and pruritis (3%) at the injection site. Fever was reported in 10% of quadrivalent HPV vaccine recipients and 9% of placebo recipients.

Report suspected reactions to the HPV vaccine or other vaccines to the Vaccine Adverse Events Reporting System (VAERS) at 800-822-7967 (toll-free) or http://vaers.hhs.gov.

CONTRAINDICATIONS

- History of immediate hypersensitivity to yeast or to any vaccine component.

PRECAUTIONS

- Quadrivalent HPV vaccine can be administered to females with minor acute illnesses (e.g., diarrhea or mild upper respiratory tract infections, with or without fever).
- Vaccination of people with moderate or severe acute illnesses should be deferred until after the illness improves.

PREGNANCY

- Quadrivalent HPV vaccine is not recommended for use in pregnancy. The vaccine has not been associated with adverse outcomes of pregnancy or adverse events to the developing fetus. However, data on vaccination during pregnancy are limited. Any exposure to vaccine during pregnancy should be reported to the vaccine pregnancy registry (1-800-986-8999).

SPECIAL SITUATIONS

- Abnormal Pap test/Positive High-Risk HPV Test/Genital Warts: Quadrivalent HPV vaccine can be given to females who have an equivocal or abnormal Pap test, a positive Hybrid Capture II® high-risk test, or genital warts. Vaccine recipients should be advised that data from clinical trials do not indicate the vaccine will have any therapeutic effect on existing Pap test abnormalities, HPV infection or genital warts. Vaccination of these
females would provide protection against infection with vaccine HPV types not already acquired.

- **Immunocompromise**: Females who are immunocompromised either from disease or medication can receive quadrivalent HPV vaccine. However, the immune response to vaccination and vaccine effectiveness might be less than in females who are immunocompetent.
- **Lactating women** can receive quadrivalent HPV vaccine.

**DOCUMENTATION**

- **Product Insert**: The product package insert on Gardasil™ contains additional vaccine information: [http://www.fda.gov/cber/label/hpvmer060806LB.pdf](http://www.fda.gov/cber/label/hpvmer060806LB.pdf)
- **Vaccine Information Statement (VIS)**: An interim VIS (9/5/06) that can be used with quadrivalent HPV vaccine can be found at [http://www.cdc.gov/nip/publications/VIS/](http://www.cdc.gov/nip/publications/VIS/).
- **Center for Disease Control Prevention Fact Sheet**: A question and answer sheet on HPV disease and the HPV vaccine can be found at: [http://www.cdc.gov/nip/vaccine/hpv/hpv-faqs.htm](http://www.cdc.gov/nip/vaccine/hpv/hpv-faqs.htm) and [http://www.cdc.gov/std/hpv/default.htm](http://www.cdc.gov/std/hpv/default.htm).
- **ACIP recommendations**: Provisional ACIP recommendations may be found at: [http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf](http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf). Final ACIP recommendations for quadrivalent HPV vaccine will later be published at [http://www.cdc.gov/nip/publications/acip-list.htm](http://www.cdc.gov/nip/publications/acip-list.htm).
- **American Academy of Pediatrics (AAP) recommendations** and other information about HPV will be available to AAP members at [http://www.cispimmunize.org/](http://www.cispimmunize.org/).
- **VFC resolution No. 6/06-2**: The VFC resolution on quadrivalent HPV vaccine may be found at: [http://www.cdc.gov/nip/vfc/acip_vfc_resolutions.htm](http://www.cdc.gov/nip/vfc/acip_vfc_resolutions.htm).
- **Vaccine Injury Compensation Program (VICP)**: HPV vaccine will be covered by the federal VICP. Information on the federal VICP and quadrivalent HPV vaccine will be found at: [http://www.hrsa.gov/vaccinecompensation/](http://www.hrsa.gov/vaccinecompensation/).

Enclosures: Order Form (11/06), HPV VIS, Timing Schedule, IMM 395

cc: DHS Immunization Branch Field Representatives
    Local Health Officers
    Local Health Department Immunization Coordinators
    Local Health Department CHDP Program Directors
    Vanessa Baird, Chief, Medi-Cal Managed Care Division, CDHS
    Marian Dalsey, M.D., Chief, Children Medical Services Branch, CDHS
    Michael Farber, M.D., Chief Medical Officer, Medi-Cal Managed Care, CDHS
    Susann Steinberg, M.D., Chief, Maternal, Child and Adolescent Health/Office of Family Planning Branch, CDHS
    Villita Lewis, Deputy Director, Benefits and Quality Monitoring, MRMIB
    Marcia Ehinger, M.D., Medi-Cal Benefits Branch, CDHS
    Kathy Chance, M.D., Children Medical Services Branch, CDHS
## VACCINES FOR CHILDREN (VFC) PROGRAM

### VACCINE ORDER FORM

#### CONTACT PERSON

**DELIVERY ADDRESS (Number and Street—No P.O. Boxes)**

**CHECK HERE IF THIS IS A NEW ADDRESS.**

**CITY**

**ZIP CODE**

**STATE USE ONLY**

**COUNTY**

**DATE**

**CHDP MEDICAL PROVIDER**

<table>
<thead>
<tr>
<th>DEPARTMENT OF HEALTH SERVICES</th>
<th>IMM-376C</th>
</tr>
</thead>
<tbody>
<tr>
<td>State of California—Health and Human Services Agency</td>
<td>DHS 8501 (11/06) Please retain a copy for your records</td>
</tr>
</tbody>
</table>

**VACCINES FOR CHILDREN (VFC) PROGRAM**

### REMARKS

**PREPARED BY:**

**SIGNATURE:**

**DATE:**

**DELIVERY:** Please specify all days and times you may receive vaccine.

**SEND:**

- Send another manufacturer’s vaccine.
- Send the manufacturer’s vaccine I requested when it is available.

### CONTACT PERSON

**TELEPHONE**

**FAX**

### VACCINES

Write in the name of the manufacturer you prefer (if any) for DTaP, hepatitis A, hepatitis B, Hib, and Tdap vaccines in the indicated spaces below.

#### REGULAR ORDER VFC VACCINES

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Number of Doses (VFC Only) Used Since Last Order</th>
<th>Dose and Size</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>DTaP/Hepatitis B/IPV Combination</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (Age 12 months–18 years)</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B (Pediatric/Adolescent)</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>IPV (Inactivated Polio Vaccine)</td>
<td>5 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Meningococcal Conjugate (ONLY for adolescents 11–18 years of age)</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal Conjugate</td>
<td>5 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Rotavirus (Live, Oral Vaccine) (ONLY for infants ages 6 - 32 weeks)</td>
<td>10 x 1 dose in 2mL tubes</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Td-Preservative Free (Age 7–18 years)</td>
<td>10 x 1 dose syringe no needle</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Tdap (Adolescent Td with acellular pertussis [booster] ages 10-18 years)</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>HPV (Human Papillomavirus) (ONLY for females 9–18 years of age)</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
</tbody>
</table>

#### REGULAR VFC VACCINES STORED IN THE FREEZER

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Number of Doses (VFC Only)</th>
<th>Dose and Size</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MMR (Combined Measles, Mumps, and Rubella)</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>Varicella (Chickenpox)</td>
<td>10 x 1 dose vials</td>
<td>doses</td>
<td></td>
</tr>
<tr>
<td>MMRV (Combined Measles, Mumps, Rubella, and Varicella [Chickenpox] vaccines for children 12 mos to 12 years)</td>
<td>10 x 1 dose vial</td>
<td>doses</td>
<td></td>
</tr>
</tbody>
</table>

### IMPORTANT

**IF THE SPECIFIC VACCINE MANUFACTURERS I HAVE INDICATED ABOVE ARE NOT AVAILABLE:**

- ✅ Send another manufacturer’s vaccine.
- ❌ Send the manufacturer’s vaccine I requested when it is available.

### INSTRUCTIONS

1. Please Print or Type.
2. Order no more than once every two months (i.e., no more than six times per year).
   - Place your order with sufficient stock on hand to allow at least 30 days for delivery. (It should not take 30 days to deliver vaccine, but this will prevent you from running out of vaccine if there is a delay in filling your order.)
3. Fax your order to the VFC Program.

### QUESTIONS

- **Toll-free:** 877-2Get-VFC (877-243-8832)
- **FAX orders to:** 877-FAXX-VFC (877-329-9832)

**VFC Program • California Department of Health Services, Immunization Branch**

850 Marina Bay Parkway, Building P • Richmond, CA 94804

---

**Notes #1:** Toxoids and vaccines not available through the VFC Program: DT-Pediatric, DTaP-Hib, OPV, tetanus, measles, MR (measles-rubella), mumps, and rubella vaccines, HBIG, and PPD.

**Notes #2:** Read the package insert to see if the product selected can be given at 10 years of age.

**STATE USE ONLY**

<table>
<thead>
<tr>
<th>State Use Only</th>
<th>Assigned</th>
<th>Approved</th>
<th>Assigned</th>
<th>Entered</th>
<th>Shipped</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHS 8501 (11/06) Please retain a copy for your records</td>
<td>IMM-376C</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**What is HPV?**

Genital human papillomavirus (HPV) is the most common sexually transmitted virus in the United States. There are about 40 types of HPV. About 20 million people in the U.S. are infected, and about 6.2 million more get infected each year. HPV is spread through sexual contact.

Most HPV infections don’t cause any symptoms, and go away on their own. But HPV is important mainly because it can cause cervical cancer in women. Every year in the U.S. about 10,000 women get cervical cancer and 3,700 die from it. It is the 2nd leading cause of cancer deaths among women around the world.

HPV is also associated with several less common types of cancer in both men and women. It can also cause genital warts and warts in the upper respiratory tract.

More than 50% of sexually active men and women are infected with HPV at sometime in their lives.

There is no treatment for HPV infection, but the conditions it causes can be treated.

**HPV Vaccine - Why get vaccinated?**

HPV vaccine is an inactivated (not live) vaccine which protects against 4 major types of HPV.

These include 2 types that cause about 70% of cervical cancer and 2 types that cause about 90% of genital warts. HPV vaccine can prevent most genital warts and most cases of cervical cancer.

Protection from HPV vaccine is expected to be long-lasting. But vaccinated women still need cervical cancer screening because the vaccine does not protect against all HPV types that cause cervical cancer.

**Who should get HPV vaccine and when?**

Routine Vaccination

- HPV vaccine is routinely recommended for girls **11-12 years of age.** Doctors may give it to girls as young as 9 years. It is given as a 3-dose series:
  - 1st Dose: Now
  - 2nd Dose: 2 months after Dose 1
  - 3rd Dose: 6 months after Dose 1

Why is HPV vaccine given to girls at this age?

It is important for girls to get HPV vaccine before their first sexual contact – because they have not been exposed to HPV. For these girls, the vaccine can prevent almost 100% of disease caused by the 4 types of HPV targeted by the vaccine.

However, if a girl or woman is already infected with a type of HPV, the vaccine will not prevent disease from that type.

Catch-Up Vaccination

- The vaccine is also recommended for girls and women **13-26 years of age** who did not receive it when they were younger.

No booster doses are recommended at this time.

HPV vaccine may be given at the same time as other vaccines.

**Some girls or women should not get HPV vaccine or should wait**

- Anyone who has ever had a life-threatening allergic reaction to yeast, to any other component of HPV vaccine, or to a previous dose of HPV vaccine should not get the vaccine. Tell your doctor if the person getting the vaccine has any severe allergies.
5 What are the risks from HPV vaccine?

HPV vaccine does not appear to cause any serious side effects.

However, a vaccine, like any medicine, could possibly cause serious problems, such as severe allergic reactions. The risk of any vaccine causing serious harm, or death, is extremely small.

Several mild problems may occur with HPV vaccine:

- Pain at the injection site (about 8 people in 10)
- Redness or swelling at the injection site (about 1 person in 4)
- Mild fever (100°F) (about 1 person in 10)
- Itching at the injection site (about 1 person in 30)
- Moderate fever (102°F) (about 1 person in 65)

These symptoms do not last long and go away on their own.

Life-threatening allergic reactions from vaccines are very rare. If they do occur, it would be within a few minutes to a few hours after the vaccination.

Like all vaccines, HPV vaccine will continue to be monitored for unusual or severe problems.

6 What if there is a severe reaction?

What should I look for?

- Any unusual condition, such as a high fever or behavior changes. Signs of a serious allergic reaction can include difficulty breathing, hoarseness or wheezing, hives, paleness, weakness, a fast heart beat or dizziness.

What should I do?

- Call a doctor, or get the person to a doctor right away.
- Tell your doctor what happened, the date and time it happened, and when the vaccination was given.
- Ask your doctor, nurse, or health department to report the reaction by filing a Vaccine Adverse Event Reporting System (VAERS) form.

Or you can file this report through the VAERS website at www.vaers.hhs.gov, or by calling 1-800-822-7967.

VAERS does not provide medical advice.

7 How can I learn more?

- Ask your doctor or nurse. They can show you the vaccine package insert or suggest other sources of information.
- Call your local or state health department.
- Contact the Centers for Disease Control and Prevention (CDC):
  - Call 1-800-232-4636 (1-800-CDC-INFO)

Pregnant women should not get the vaccine. The vaccine appears to be safe for both the mother and the unborn baby, but it is still being studied. Receiving HPV vaccine when pregnant is not a reason to consider terminating the pregnancy. Women who are breast feeding may safely get the vaccine.

People who are mildly ill when the shot is scheduled can still get HPV vaccine. People with moderate or severe illnesses should wait until they recover.

Any woman who learns that she was pregnant when she got HPV vaccine is encouraged to call the HPV vaccine in pregnancy registry at 800-986-8999.

Information from this registry will help us learn how pregnant women respond to the vaccine.

Any woman who learns that she was pregnant when she got HPV vaccine is encouraged to call the HPV vaccine in pregnancy registry at 800-986-8999.

Information from this registry will help us learn how pregnant women respond to the vaccine.
Every Fall:
Flu Vaccine

For School-Age Kids
Before Kindergarten
Polio, DTaP, MMR #2, and Varicella #2.

Before 7th Grade
Varicella, HPV

Final dose of HepB and PCV series should be given at 24 months:
2 months and 4 month interval doses. 2 months and 6 months between doses.

MMR vaccine can be given both doses and Varicella vaccine can be included.

This is a suggested schedule. For detailed information, consult the latest “Recommended Childhood Immunization Schedule, United States 2006.”

1 HepB series: In absence of documented birth-dose, a schedule starting at 2 months is acceptable. If using combination vaccines, a fourth dose is allowable. If using ComVax® (combined Hib and HepB vaccine), final dose is at 12-15 months.

2 The first dose should be given between 6-12 weeks. Maximum age for Rotavirus vaccine is 32 weeks.

3 This six month Hib dose can be skipped if Pedvax HIB® and/or ComVax® are used exclusively for the six month Hib dose.

4 Final dose of Hib and PCV series should be given at ≥12 months.

5 MMRV vaccine can be used when both MMR and Varicella vaccines are indicated.

6 All routine vaccines are available in a thimerosal-free option. See California Health and Safety Code §124172.

7 Human Papillomavirus vaccine is recommended for girls only.

Immunization Timing
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Code</th>
<th>Vaccine Source</th>
<th>Age</th>
<th>Rate</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP</td>
<td>45</td>
<td>Vaccines For Children (VFC)</td>
<td>2 months thru 6 years, 11 months</td>
<td>$9.00</td>
<td>Required</td>
</tr>
<tr>
<td>DT Pediatric</td>
<td>59</td>
<td>Purchased</td>
<td>2 months thru 6 years, 11 months</td>
<td>$10.93</td>
<td></td>
</tr>
<tr>
<td>Td Adult (DECAVAC™)</td>
<td>58</td>
<td>VFC</td>
<td>7 years thru 18 years, 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td>Td Adult</td>
<td>60</td>
<td>Purchased</td>
<td>7 years thru 20 years, 11 months</td>
<td>$13.96</td>
<td></td>
</tr>
<tr>
<td>Tdap</td>
<td>72</td>
<td>VFC</td>
<td>10 years thru 18 years, 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>65</td>
<td>VFC (Pediatric)</td>
<td>1 year thru 18 years, 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>66</td>
<td>Purchased (Adult)</td>
<td>19 years thru 20 years, 11 months</td>
<td>$65.48</td>
<td></td>
</tr>
<tr>
<td>HBIG</td>
<td>41 + 57</td>
<td>Purchased</td>
<td>Birth thru 20 years, 11 months</td>
<td>$168.12</td>
<td>Reason for administration</td>
</tr>
<tr>
<td>Hepatitis B/Hib Combination</td>
<td>56</td>
<td>VFC</td>
<td>2 months thru 4 years, 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B Lower Dose (Pediatric/Adolescent)</td>
<td>40</td>
<td>VFC</td>
<td>Birth thru 18 years, 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B Higher Dose (Adult)</td>
<td>42</td>
<td>VFC</td>
<td>11 years thru 15 years, 11 months</td>
<td>$9.00</td>
<td>(Use this code for two dose adolescent schedule)</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>51</td>
<td>Purchased</td>
<td>19 years thru 20 years, 11 months</td>
<td>$38.17</td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>38</td>
<td>VFC</td>
<td>2 months thru 18 years, 11 months</td>
<td>$9.00</td>
<td>High risk factor, if older than 5 years</td>
</tr>
<tr>
<td></td>
<td>63</td>
<td>Purchased</td>
<td>19 years thru 20 years, 11 months</td>
<td>$16.82</td>
<td>High risk factor</td>
</tr>
<tr>
<td>Human Papillomavirus</td>
<td>76</td>
<td>VFC</td>
<td>9 years thru 18 years, 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>53</td>
<td>VFC</td>
<td>6 months thru 18 years, 11 months</td>
<td>$9.00</td>
<td>High risk factor</td>
</tr>
<tr>
<td></td>
<td>54</td>
<td>Purchased</td>
<td>6 months thru 20 years, 11 months</td>
<td>$13.76</td>
<td>High risk factor</td>
</tr>
<tr>
<td>FluMist</td>
<td>71</td>
<td>VFC</td>
<td>5 years thru 18 years, 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
</tbody>
</table>

1. Total reimbursement, includes administration fee.
2. Only for infants with HBsAg (+) mothers and for children exposed to known/suspected HBsAg (+) blood/tissue fluids.
3. Adolescent two dose immunization schedule, currently approved for ages 11 years thru 15 years, 11 months.
4. Only for females.
5. For one dose annually, except for children 5 years through 8 years, 11 months who have never received an influenza immunization. These children should receive two doses, with an interval of 42 days.
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Code</th>
<th>Vaccine Source</th>
<th>Age</th>
<th>Rate</th>
<th>Comment Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMR</td>
<td>33</td>
<td>VFC</td>
<td>12 months thru 18 years, 11 months</td>
<td>$ 9.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>Purchased</td>
<td>19 years thru 20 years, 11 months</td>
<td>$ 38.27</td>
<td></td>
</tr>
<tr>
<td>MMRV</td>
<td>74</td>
<td>VFC</td>
<td>12 months thru 18 years, 11 months</td>
<td>$ 9.00</td>
<td></td>
</tr>
<tr>
<td>Measles b</td>
<td>34</td>
<td>Purchased</td>
<td>12 months thru 20 years, 11 months</td>
<td>$ 21.29</td>
<td>Reason for administration</td>
</tr>
<tr>
<td>Meningococcal Conjugate Vaccine (MCV4)</td>
<td>69</td>
<td>VFC</td>
<td>11 years thru 18 years 11 months</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>70 + 73</td>
<td>Purchased</td>
<td>19 years thru 20 years 11 months</td>
<td>$101.84</td>
<td></td>
</tr>
<tr>
<td>Pediartix TM</td>
<td>68</td>
<td>VFC</td>
<td>2 months thru 6 years, 11 months</td>
<td>$ 9.00</td>
<td></td>
</tr>
<tr>
<td>Polio – Inactivated</td>
<td>39</td>
<td>VFC</td>
<td>2 months thru 18 years, 11 months</td>
<td>$ 9.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>64</td>
<td>Purchased</td>
<td>19 years thru 20 years, 11 months</td>
<td>$ 29.84</td>
<td>High risk factor</td>
</tr>
<tr>
<td>Pneumococcal Polysaccharide (23PS)</td>
<td>55</td>
<td>Purchased</td>
<td>2 years thru 20 years, 11 months</td>
<td>$ 20.74</td>
<td>High risk factor</td>
</tr>
<tr>
<td></td>
<td>67</td>
<td>VFC</td>
<td>1 month thru 4 years, 11 months</td>
<td>$ 9.00</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal, heptavalent (Prevnar)</td>
<td>67</td>
<td>VFC</td>
<td>1 month thru 4 years, 11 months</td>
<td>$ 9.00</td>
<td></td>
</tr>
<tr>
<td>Rotavirus b</td>
<td>75</td>
<td>VFC</td>
<td>6 weeks thru 32 weeks</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td>Rubella b</td>
<td>36</td>
<td>Purchased</td>
<td>12 months thru 20 years, 11 months</td>
<td>$ 24.50</td>
<td>Reason for administration</td>
</tr>
<tr>
<td>Varicella</td>
<td>46</td>
<td>VFC</td>
<td>12 months thru 18 years, 11 months</td>
<td>$ 9.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>52</td>
<td>Purchased</td>
<td>19 years thru 20 years, 11 months</td>
<td>$ 48.94</td>
<td></td>
</tr>
</tbody>
</table>

1. Total reimbursement, includes administration fee.
2. For individuals with a contraindication to rubella or mumps vaccine.
3. Measles vaccine (or, if not available, MMR) is recommended in children as young as 6 months, in outbreak situations or for international travel.
4. Oral vaccine.
5. For individuals with a contraindication to measles or mumps vaccine.